Blueprint Medicines (BPMC) Tops Q1 EPS by 11c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.79), $0.11 better than the analyst estimate of ($1.90). Revenue for the quarter came in at $62.73 million versus the consensus estimate of $38.96 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Cloudflare Inc. (NET) PT Raised to $330 at Citizens on Infrastructure Subsector Strength
• Citi maintains neutral rating on Domino's Pizza with $335 target
• Brookfield and CPP Investments to buy LXP Industrial for $5.2B